Usana Health Sciences (USNA) Cost of Revenue (2010 - 2026)

Usana Health Sciences (USNA) has reported Cost of Revenue for 17 consecutive years, with $59.4 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Cost of Revenue rose 13.33% year-over-year to $59.4 million; the TTM figure through Apr 2026 stood at $207.8 million (up 21.84% YoY), while the FY2026 annual figure was $200.9 million, up 24.59% from the prior year.
• Cost of Revenue advanced to $59.4 million in Q2 2026 per USNA's latest filing, from $49.4 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $67.8 million in Q1 2022 and bottomed at $38.6 million in Q4 2024.
• Historically, Cost of Revenue has averaged $47.8 million across 5 years, with a median of $47.5 million in 2022.
• Annual changes were most pronounced in 2022 — Cost of Revenue slumped 31.53% — and 2026, when it gained 28.16%.
• Usana Health Sciences' Cost of Revenue stood at $46.4 million in 2022, then declined by 8.85% to $42.3 million in 2023, then retreated by 8.9% to $38.6 million in 2024, then rose by 26.62% to $48.8 million in 2025, then grew by 21.76% to $59.4 million in 2026.
• Business Quant data shows USNA's Cost of Revenue at $59.4 million in Q2 2026, $49.4 million in Q1 2026, and $48.8 million in Q3 2025.